If I moved my entire position out of GERN suddenly you'd be running for the exits. I'm stuck here like the rest. I have however started to diversify elsewhere to realize better re3turns within a more reasonable time frame.
I've repeated my broker doesn't allow me to short GERN but believe who you will. As a rule I stay clear of companies with such a substantial short position that is near max. Anymore would require naked shorting , far beyond my ability or interest. I'm dissing GERN's SP performance over the year as I have lost over $X00,000 buying just before the FDA's hold. I was not the one that bought the 25 cent puts 2-3 days before and made $6mil. That was probably someone much more sophisticated with several handles like yourself.
This board is for information and opinion, doubt it influences SP. Most stocks that move upwards steadily have rather dull message boards. This one is chalk full of actors and ferry dust.
they were saying that at the 2013 ASH, 2014 was recap of 2013 and the SP sits at $3 cause show me Scarlet still has a learning curve to overcome.
Irish, I supported GERN for over a year now. Glad to have helped fund the research into IMET and contribute to a worthwhile cause in helping extend peoples lives as with John but what I'm seeing here is perhaps a top heavy overly compensated management team with very little inside ability to push this drug through the required FDA loops in a timely manner. You yourself said Tefferi wasn't the 'BIG' corporate type so I doubt he and the Janssen team will see eye to eye on much going forward with IMET and who knows whether Jansen can actually replicate the same, if not obtain better results as did the MAYO without him. He certainly isn't in the line light like he was in 2013 ASH or last year in the many IMET related conferences you attended & he spoke in. Whenever they ? get there going forward with MF PHASE II expansion, it may take another 6 months to a year. I don't have the luxury of time anymore.
Currently SP is valued at 2.6x cash and it sits here. I'm beginning to sense my investment loss went to pay for a few porches that I'll never get to riding in. I still have a substantial amount left invested here but slowly moving my remaining position elsewhere. Good luck to you and John and please keep the board informed when there is an update as management certainly isn't trying hard. Besides I swear you understand the science behind IMET far better than Chippy. Thanx ;=3)
Better take the ride on the MEIP river way. No log jambs, just plain good old fundamentals and a sense of moving forward.
The $35 million was a one time upfront payment from Jassen. The market is well aware this is not related to earnings from sales. The shorts linger while the MM is master bating with the SP every day until GERN gets news, whenever, whatever. Until they cover this disgusting game in public continues.
She has posted on the MPN forum blog a few times already.
It's just that Irish sounds far more informed than Scarlet talking about the science behind IMET and certainly comes across with far more compassion and conviction than he does. So as a company spokesperson /advocate she would be far better speaking at public functions than a former porch race car driver would. Although I wouldn't mind seeing his diving slides & videos.
MEIP is obviously not on the MF space however when it comes to combo treatment they're getting notable results in AML & MDS, a market space that GERN must go after if it's to succeed as a company.
The Company completed enrollment in a randomized, placebo-controlled Phase II study of Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk MDS. The Company plans to unblind the study and report topline data early next month, hence to movement in SP.
from their web site;
"Pracinostat is an oral histone deacetylase (HDAC) inhibitor that has been tested in a number of Phase I and Phase II clinical trials in advanced hematologic disorders and solid tumor indications in both adult and pediatric patients. Pracinostat has been generally well tolerated in more than 300 patients to date, with manageable side effects often associated with drugs of this class, including fatigue, myelosuppresion and gastrointestinal toxicity. In a Phase I dose-escalation trial, Pracinostat demonstrated evidence of single-agent activity in elderly acute myeloid leukemia (AML) patients, including two out of 14 (14%) who achieved a CR, with durable responses persisting 206+ and 362 days, respectively. In addition, results from a pilot study of Pracinostat in combination with azacitidine in patients with advanced MDS showed an overall response rate of 90% (nine out of 10), including six patients who achieved a CR.
Earlier in Dec, significant clinical activity from a Phase II study of Pracinostat in combination with azacitidine in elderly patients with newly diagnosed AML were reported at the American Society of Hematology (ASH) Annual Meeting. According to the presentation, 15 of 33 evaluable patients (45%) achieved the primary endpoint of CR plus complete response with incomplete blood count recovery (CRi) plus morphologic leukemia-free state. No patient who achieved a clinical response has progressed. The Company plans to report full top line data from all 50 patients enrolled in the study in June 2015."
"MDS; Of the first 28 patients who received Pracinostat in combination with azacitidine (marketed as Vidaza®) or decitabine (marketed as Dacogen®) after progressing while being treated with the same HMA alone, three have now achieved clinical responses, one partial response (PR) and two marrow complete responses (mCR), exceeding the pre-specified clinical improvement rate for expansion of study enrollment."
you weren't the guy that bought those 25cent puts 2-3 days before the FDA hold was announced on March 12 were you Ryan?